Decline of popliteal artery flow-mediated dilation with aging and possible involvement of asymmetric dimethylarginine in healthy men

Akihiro Nakamura1 · Shoko Kajitani2 · Kenjiro Sato1 · Masanori Kanazawa1 · Masateru Kondo1 · Hideaki Endo1 · Eiji Nozaki1

Received: 8 February 2019 / Accepted: 5 April 2019 / Published online: 23 April 2019
© The Author(s) 2019

Abstract
Purpose We examined the influences of age and gender on flow-mediated endothelial function and the involvement of the competitive inhibition of \( \text{L-arginine} \) in endothelial function.

Methods We measured brachial and popliteal flow-mediated vasodilation (FMD) responses, nitrate/nitrite (NOx) concentrations, and plasma levels of asymmetric dimethylarginine (ADMA) in four healthy, nonsmoking groups: young men (mean 26 ± 2 years, \( n = 17 \)), middle-aged men (mean 50 ± 3 years, \( n = 19 \)), young women (mean 27 ± 2 years, \( n = 16 \)), and middle-aged women (mean 51 ± 2 years, \( n = 18 \)).

Results In young men, we found no significant differences between brachial and popliteal artery FMDs (10.6 ± 1.5 vs 8.7 ± 1.6%, \( p = 0.06 \)). However, the popliteal artery FMD was significantly lower than the brachial artery FMD in middle-aged men (11.4 ± 1.5 vs 6.4 ± 1.0%, \( p < 0.001 \)). In women, we found no significant differences between brachial and popliteal artery FMDs in young and middle-aged individuals (young, \( p = 0.17 \); middle-aged, \( p = 0.08 \)). Popliteal artery FMD correlated with plasma NOx and ADMA levels as well as with the NOx/ADMA ratio in men but not in women (\( r = 0.485, -0.544, \) and 0.672, respectively).

Conclusion We concluded that a decrease in flow-mediated endothelial function in arteries of the lower extremities was evident in healthy middle-aged men, but not in middle-aged women. The competitive inhibition of \( \text{L-arginine} \) may contribute to this decrease in men.

Keywords Popliteal artery · Brachial artery · Flow-mediated vasodilation · Asymmetric dimethylarginine · Nitric oxide

Introduction
Atherosclerotic lesions are generally recognized as having a nonuniform distribution in the vasculature [1]. With regard to the extremities, it is a well-known fact that atherosclerotic lesions develop first in the arteries of the lower extremities before progressing to those of the upper extremities. This difference in the upper and lower extremities of humans is also supported by evidence of a higher incidence of atherosclerosis in the lower extremities, known as peripheral arterial disease (PAD) [2, 3].

Endothelium-dependent vasodilation plays an important role in the pathogenesis of many atherosclerotic diseases including PAD [4, 5]. Measurement of flow-mediated vasodilation (FMD) in the brachial artery by high-resolution ultrasound has been widely used as a noninvasive method for assessing endothelial function [5, 6]. The decrease in brachial artery FMD is used as a surrogate marker of cardiovascular function or a predictive marker of future cardiovascular events and has been observed in patients with cardiovascular disease [7] and hyperlipidemia [8]. Aging is a well-known risk factor for cardiovascular disease, and a consequence of aging is impaired vascular endothelial function [9, 10]. Although age-related declines in the vasodilator
responsiveness of the brachial artery have been reported in healthy men without risk factors [11–13], the influence of aging on FMD responses in the lower extremities in healthy subjects has not been well studied. Gender differences have also been associated with the development of atherosclerosis, and brachial artery FMD in young women is greater than that in young and elderly men [11–15]. However, previous studies that examined the effect of gender differences on FMD responses have been limited to the brachial artery, and this effect has not been fully elucidated in the lower extremity arteries, especially in healthy subjects.

Endothelial dysfunction can also be assessed noninvasively by the measurement of circulating markers such as asymmetric dimethylarginine (ADMA), which is an endogenous and competitive inhibitor of nitric oxide (NO) synthase and acts as a regulator of the l-arginine/NO pathway [16, 17]. It has been shown that FMD is related to endothelium-derived NO bioavailability [18]. Although an inverse association between plasma ADMA levels and brachial artery FMD has been demonstrated not only in patients with atherosclerotic risk factors [19, 20] but also in healthy subjects [21, 22], the association between this marker and lower extremity artery FMD has not been well studied in healthy subjects.

We hypothesized that lower but not upper extremity artery FMD would be decreased in middle-aged subjects compared with young adults, and that plasma ADMA levels would be inversely associated with lower extremity artery FMD in healthy men and women. To test these hypotheses, using the brachial and popliteal arteries, we examined whether FMD responses in the upper and lower extremity arteries were affected by aging and gender, and whether an association between plasma ADMA levels and upper or lower extremity artery FMD existed in healthy men and women.

Materials and methods

Study subjects

Thirty-six healthy men (17 young and 19 middle-aged adults) and 34 healthy women (16 young and 18 middle-aged adults) volunteered to participate in this study. All subjects were nonobese (body mass index <25.0 kg/m²), had normotensive resting blood pressure ≤140/90 mmHg, and had a negative smoking history. All subjects were normally active, were not taking any prescription medications, had clinically normal blood chemistry data [total cholesterol (TC) ≤240 mg/dl, low-density lipoprotein cholesterol (LDL-C) <140 mg/dl, high-density lipoprotein cholesterol (HDL-C) ≥40 mg/dl, and hemoglobin A1c (HbA1c) <5.7%], and had a resting supine ankle-brachial index (ABI) from 0.90 to 1.30. The subjects were free of obvious chronic diseases, as determined by a medical questionnaire and a physical examination including resting electrocardiogram. No subjects were taking any supplements with significant hemodynamic effects.

Study protocol

We measured FMD for the assessment of endothelium-dependent vascular function in both the brachial and the popliteal arteries, and measured plasma ADMA levels for the assessment of endothelial dysfunction in all subjects. The subjects were instructed to fast overnight and were prohibited from food or exercise and from consuming caffeine, vitamins, or alcohol within 12 h before the start of the study. The study began at 9:00 a.m. The subjects were kept in a supine or seated position in a quiet, air-conditioned room with a stable temperature of 23 ± 1 °C during the study. At the beginning of the study, blood pressure and pulse rate were measured and blood sampling was performed. One hour after blood sampling, brachial artery FMD was measured. After the subject had maintained a seated position in the room for 2 h, popliteal artery FMD was measured. Both brachial and popliteal FMD were measured by one trained ultrasonographer blinded to the details of the study.

Measurement of brachial and popliteal artery FMD

Brachial artery FMD [6] was measured with a semi-automated edge-detection system (UNEXEF18G; UNEX, Nagoya, Japan) according to the guidelines [23]. Briefly, the right brachial artery was scanned by high-resolution ultrasound with a 10-MHz linear array transducer for longitudinal and transverse images, while the subject was in a supine position after resting for ≥15 min. A sphygmomanometric cuff attached to the UNEXEF18G was positioned around the right forearm, and images of the artery were obtained on the proximal portion of the antecubital fossa. After recording of baseline images, the cuff was inflated to at least 50 mmHg above systolic blood pressure for 5 min and then deflated. The postdeflation arterial images were obtained in a similar manner as those for reactive hyperemia, and artery diameters were measured for 2 min with R-wave-synchronized automated edge-detection software. Brachial artery FMD was calculated as the maximal postdeflation diameter relative to the average baseline diameter.

Popliteal artery FMD was measured in a similar fashion to brachial FMD measurement using the UNEXEF18G [24]. After 2 h of rest following brachial FMD measurement, the subject was placed in a prone position. A sphygmomanometric cuff was positioned around the right calf, and the images of the artery at baseline were obtained on the proximal portion of the popliteal fossa. After reactive hyperemia produced by inflation of the cuff on the calf to
at least 50 mmHg above systolic blood pressure of the leg for 5 min, continuous measurement of artery diameter was performed, and popliteal artery FMD was calculated with the same formula as that for brachial artery FMD: (maximal postdeflation diameter – baseline diameter)/(baseline diameter) × 100.

After 15 min of rest from brachial or popliteal FMD measurement, a resting scan was recorded and a sublingual nitroglycerin spray (0.3 mg; Toa Eiyo, Tokyo, Japan) was administered. The last scan was performed 3 min later. The change in diameter of the brachial or popliteal artery was expressed as percent dilation by nitroglycerin (NTG) (NMD: NTG-mediated vasodilation). To assess the reproducibility of brachial and popliteal FMDs with 80% power and α-type error of 5% in statistical analysis, a total of 60 measurements of brachial and popliteal artery diameter (each three times in 10 subjects) were intra-individually conducted. The coefficient of variation for repeated measurements of brachial and popliteal artery diameter at flow-mediated dilation was 1.38 ± 0.03 and 1.43 ± 0.02%, respectively, with this equipment.

Blood sampling

Blood samples were obtained from the left antecubital vein with a 23-gauge polyethylene catheter, collected into heparinized tubes as plasma or into collection tubes containing serum separator gel as serum and immediately centrifuged to obtain the supernatant on the morning of the study (9:00 a.m.), 2 h before the measurement of brachial artery FMD. The plasma levels of NO metabolites (NOx: nitrite + nitrate) were measured at a contract laboratory (SRL, Tokyo, Japan), according to the Griess method. The samples were deproteinated and separated into nitrates and nitrates. After all the nitrates were reduced to nitrates, the samples were reacted with (R)-1-(1-naphththyl)ethylamine, and the product was determined based on the absorbance at 540 nm [25]. The plasma levels of ADMA were also measured at SRL by high-performance liquid chromatography (HPLC): Hitachi L-7480 system equipped with a fluorescence detector for excitation at 348 nm and emission at 540 nm [26]. The plasma levels of lipid parameters [TC, triglycerides (TG), LDL-C, HDL-C] and glucose parameters [fasting plasma glucose, HbA1c] were measured by standard methods (TC and TG by an enzymatic method; LDL-C and HDL-C by a direct method; HbA1c by HPLC) in our hospital laboratory.

Statistical analysis

Values are expressed as means ± standard deviation for continuous variables and as numbers and percentages for categorical variables. Differences between two groups were assessed using Student’s unpaired t test or the Mann–Whitney U test for continuous variables and the chi-square test for categorical variables. Correlation between two parameters was determined by simple linear regression analysis. A two-sided p value ≤ 0.05 was considered to indicate statistical significance. All statistical analyses were performed with SPSS version 14.0 (SPSS, Chicago, IL, USA).

Results

Characteristics of study subjects

The characteristics of the subjects, 36 healthy male volunteers (17 young and 19 middle-aged men) and 34 healthy female volunteers (16 young and 18 middle-aged women), are summarized in Table 1. The mean ages of the young and middle-aged men were 26 ± 2 and 50 ± 3 years, respectively, while those of the women were 27 ± 2 and 51 ± 2 years, respectively. No subjects had a BMI ≥ 25 kg/m² or a history of smoking. C-reactive protein was not significantly different among the four groups.

Concentration of plasma NOx and ADMA

Plasma NOx levels were lower in middle-aged men and women than in young men and women, although these differences were not statistically significant (men 29.7 ± 14.5 vs 40.3 ± 17.2 µmol/L, p = 0.098; women 40.8 ± 14.5 vs 49.1 ± 11.4 µmol/L, p = 0.076). Plasma ADMA levels were higher in middle-aged men than in young men, although this difference was not statistically significant (0.39 ± 0.06 vs 0.35 ± 0.04 µmol/L, p = 0.496). The ratio of plasma NOx levels to ADMA levels was significantly lower in middle-aged men than in young men (81.5 ± 47.2 vs 125.3 ± 49.2, p = 0.010), but was not significantly different between young and middle-aged women (152.2 ± 49.0 vs 120.3 ± 49.5, p = 0.069) (Table 1).

FMD of brachial and popliteal arteries in men and women

Three groups (young men, middle-aged men, and middle-aged women) had significantly greater baseline vessel sizes in the popliteal artery than in the brachial artery (young men 5.00 ± 0.48 vs 3.88 ± 0.33 mm, p < 0.001; middle-aged men 5.80 ± 0.10 vs 3.97 ± 0.41 mm, p < 0.001; middle-aged women 4.06 ± 0.64 vs 3.31 ± 0.38 mm, p = 0.005). In young women, baseline vessel size was similar in the brachial and popliteal arteries (3.43 ± 0.53 vs 3.73 ± 0.61 mm; p = 0.20)
Table 1  Subject characteristics

| Variable                        | Young men (n = 17) | Middle-aged men (n = 19) | p value | Young women (n = 16) | Middle-aged women (n = 18) | p value |
|---------------------------------|-------------------|--------------------------|---------|----------------------|---------------------------|---------|
| Age, years                      | 26 ± 2            | 50 ± 3                   | <0.001  | 27 ± 2               | 51 ± 2                     | <0.001  |
| Height, cm                      | 173 ± 5           | 172 ± 6                  | 0.61    | 157 ± 7              | 157 ± 3                    | 0.80    |
| Weight, kg                      | 64 ± 6            | 64 ± 6                   | 0.88    | 48 ± 6               | 54 ± 8                     | 0.16    |
| BMI, kg/m²                      | 22 ± 2            | 21 ± 1                   | 0.55    | 19 ± 1               | 22 ± 3                     | 0.058   |
| Resting SBP, mmHg               | 120 ± 7           | 126 ± 12                 | 0.20    | 111 ± 7              | 119 ± 13                   | 0.15    |
| Resting DBP, mmHg               | 66 ± 7            | 85 ± 12                  | 0.003   | 65 ± 9               | 78 ± 7                     | 0.006   |
| Current or former smokers (%)   | 0 (0)             | 0 (0)                    | 1.00    | 0 (0)                | 0 (0)                      | 1.00    |
| Postmenopausal (%)              | –                 | –                        | –       | 0 (0)                | 10 (56)                    | <0.001  |
| Oral contraceptive use (%)      | –                 | –                        | –       | 0 (0)                | 0 (0)                      | 1.00    |
| CRP, mg/dl                      | 0.12 ± 0.11       | 0.16 ± 0.12              | 0.33    | 0.11 ± 0.10          | 0.13 ± 0.10                | 0.53    |

Lipid markers

| Total cholesterol, mg/dl        | 197 ± 32          | 192 ± 34                  | 0.88    | 187 ± 41             | 218 ± 21                   | 0.032   |
| Triglycerides, mg/dl           | 89 ± 36           | 64 ± 34                   | 0.25    | 54 ± 26              | 75 ± 36                     | 0.23    |
| LDL-cholesterol, mg/dl         | 110 ± 25          | 109 ± 39                  | 0.93    | 91 ± 13              | 113 ± 25                    | 0.021   |
| HDL-cholesterol, mg/dl         | 67 ± 13           | 70 ± 19                   | 0.58    | 85 ± 32              | 90 ± 18                     | 0.72    |

Glucose markers

| FPG, mg/dl                     | 94 ± 10           | 104 ± 12                  | 0.086   | 96 ± 7               | 96 ± 10                     | 0.90    |
| HbA1c, %                       | 5.3 ± 0.3         | 5.5 ± 0.5                 | 0.19    | 5.3 ± 0.3            | 5.6 ± 0.2                   | 0.022   |

Endothelial biomarkers

| NOx, µmol/l                    | 40.3 ± 17.2       | 29.7 ± 14.5               | 0.098   | 49.1 ± 11.4          | 40.8 ± 14.5                 | 0.076   |
| ADMA, µmol/l                   | 0.34 ± 0.09       | 0.39 ± 0.06               | 0.052   | 0.34 ± 0.06          | 0.35 ± 0.04                 | 0.496   |
| NOx/ADMA                       | 125.3 ± 49.2      | 81.5 ± 47.2               | 0.010   | 152.2 ± 49.0         | 120.3 ± 49.5                | 0.069   |

Data are presented as means ± SD for continuous variables and as percentages for categorical variables.

BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, CRP C-reactive protein, LDL low-density lipoprotein, HDL high-density lipoprotein, FPG fasting plasma glucose, HbA1c hemoglobin A1c, NTG nitroglycerin, NOx nitrate + nitrite, ADMA asymmetric dimethylarginine

Table 2  Brachial vs popliteal artery measurements in men and women

| Measurement                        | Young men (n = 17) | Middle-aged men (n = 19) | p value | Young women (n = 16) | Middle-aged women (n = 18) | p value |
|------------------------------------|--------------------|--------------------------|---------|----------------------|---------------------------|---------|
| Baseline diameter, mm              |                    |                          |         |                      |                           |         |
| Brachial artery                     | 3.88 ± 0.33        | 3.97 ± 0.41              | 0.27    | 3.43 ± 0.53          | 3.31 ± 0.38               | 0.34    |
| Popliteal artery                    | 5.00 ± 0.48†       | 5.80 ± 0.10†             | 0.016   | 3.73 ± 0.61          | 4.06 ± 0.64†              | 0.30    |
| FMD, %                             |                    |                          |         |                      |                           |         |
| Brachial artery                     | 10.6 ± 1.5         | 11.4 ± 1.5               | 0.12    | 12.9 ± 1.3           | 11.9 ± 2.4                | 0.15    |
| Popliteal artery                    | 8.7 ± 1.6          | 6.4 ± 1.0†               | <0.001  | 11.5 ± 2.0           | 10.5 ± 2.0                | 0.18    |
| NMD, %                             |                    |                          |         |                      |                           |         |
| Brachial artery                     | 17.6 ± 2.3         | 18.1 ± 2.7               | 0.38    | 19.7 ± 2.5           | 19.2 ± 3.4                | 0.71    |
| Popliteal artery                    | 16.4 ± 2.9         | 15.9 ± 3.1               | 0.45    | 18.6 ± 2.3           | 17.9 ± 3.1                | 0.52    |
| FMD/NMD ratio, %                   |                    |                          |         |                      |                           |         |
| Brachial artery                     | 67.7 ± 9.9         | 63.8 ± 7.4               | 0.18    | 68.3 ± 7.6           | 62.5 ± 7.2                | 0.53    |
| Popliteal artery                    | 56.3 ± 5.7†        | 42.8 ± 4.1†              | <0.001  | 59.8 ± 5.9†          | 56.1 ± 6.6†               | 0.10    |

Data are presented as means ± SD.

FMD flow-mediated vasodilation, NMD nitroglycerin-mediated vasodilation

† p < 0.01 and † p < 0.001 comparing brachial and popliteal artery, respectively.
extremity artery FMD with respect to age and gender. The main findings of this study were that popliteal artery FMD did not significantly differ from brachial artery FMD in healthy young men or in healthy young and middle-aged women, but was significantly smaller than brachial artery FMD in healthy middle-aged men; and that popliteal artery FMD correlated well with plasma NOx and ADMA levels and with the NOx/ADMA ratio in men, but not in women. These findings suggest that the decline in vascular endothelial function associated with aging differs between leg and arm conduit arteries in healthy men, but not in women younger than the early 50s.

Aging is recognized as an independent risk factor for the development of atherosclerosis [27]. Age-related hemodynamic and anatomic changes in the cardiovascular system are known to be associated with functionally impaired vascular responses, particularly endothelium-dependent vasodilation [11, 28]. Previous studies have demonstrated that the effect of aging on FMD response in the upper extremities differs between healthy men and women. Corretti et al. [28] showed that endothelium-dependent vasoactivity differentiated older (>40 years of age) men from younger (<40 years of age) normal men based on the FMD response in the brachial artery, and that this response did not differentiate normal older premenopausal (>40 years of age) women from younger (<40 years of age) normal women. Celermajer et al. [11] showed that an age-related decline in brachial artery FMD occurred in women starting from 53 years of age. Our finding showing no difference in brachial artery FMD between young and middle-aged healthy women supports the stability of brachial artery FMD responses in healthy women until the early 50s. When young and middle-aged healthy men were compared, there was no significant difference in brachial artery FMD in our study. This finding was compatible with that of other studies showing similar brachial artery FMD responses in Swedish men at 35 and 55 years of age [29]. Although the starting age of endothelial-dependent vasodilation decline in men was reported from 41 years of age [11], our study suggests that it may be later than that age.

The nature of the vasculature is nonuniform, and arteries in the lower extremities are more sensitive to the development of atherosclerosis than those in the upper extremities. Arterial diseases typified by PAD are more common in lower extremity arteries than in upper extremity arteries, and they are highly correlated with the progression of coronary artery diseases [30]. Although the upper extremities are well-established clinical research models for noninvasive assessment of endothelial function, they are of limited consequence to systemic cardiovascular control because of their small muscle volume and blood flow requirements. Measurement of FMD in the lower extremity arteries would thus provide meaningful information for better understanding of the effects of aging on endothelial function. Although several
Clinical studies have revealed attenuated vascular endothelial responses in the lower extremities of subjects with cardiovascular diseases [31], there is a paucity of FMD studies regarding age-related declines in vascular function in lower extremity arteries [32].

Our study demonstrated that endothelial flow-dependent dysfunction with aging was greater in lower extremity arteries than in upper extremity arteries in healthy men. Nishiyama et al. [32] reported that the absolute values of FMD did not differ between the brachial and popliteal arteries in

Fig. 1 Correlations between FMD and plasma NOx, ADMA, and NOx/ADMA ratio in men. Left panels showing the relationship between brachial FMD and NOx (a), ADMA (b), and NOx/ADMA ratio (c); right panels showing the relationship between popliteal FMD and NOx (d), ADMA (e), and NOx/ADMA ratio (f). FMD flow-mediated dilation, NOx nitrate+nitrite, ADMA asymmetric dimethylarginine.
young healthy subjects (mean age 26 ± 2 years), whereas those in the popliteal artery were significantly attenuated compared with the brachial arteries in older healthy subjects (mean age 72 ± 1 years). We examined popliteal artery FMD in middle-aged men (mean age 50 ± 3 years) compared with that in young men (mean age 26 ± 2 years). The age of healthy men showing a decline of leg artery endothelial function was lower than that of subjects demonstrated before by Nishiyama et al. [32]. In women, there were no significant differences in FMD between young and middle-aged healthy subjects in the brachial and popliteal arteries. These findings, which are compatible with those of previous studies [24], suggest that FMD is preserved until the early 50s not only in the brachial arteries but also in the popliteal arteries. However, the exact reason why the decrease in popliteal artery FMD was not observed in women is still unclear. The effect of sex hormonal factors may best explain the gender difference in age-related decline in endothelial flow-dependent function. Estrogens have been shown to protect premenopausal women from the decrease in endothelial function via an increase in blood flow and subsequently shear stress [33]. They have also been reported to be associated with a lower production of reactive oxygen species (ROS), which were found to contribute to arterial stiffening in estrogen-deficient postmenopausal women [34]. In this study, all middle-aged women were in their early 50s (mean 51 ± 2 years), and about half of them were postmenopausal. Although it is unknown how long the protective effects of estrogens against endothelial injury last after menopause, it seems that the women at the age around the time of menopause are protected from the development of endothelial flow-mediated dysfunction with aging.

In this study, there was a difference in baseline diameters of popliteal arteries between young and middle-aged men. Baseline arterial diameters, which are part of the calculation of percentage FMD, have been reported to influence FMD responses by impacting shear stress on the arterial wall [35]. It is unclear whether FMD responses might be influenced by the structural differences, but the decline in popliteal artery FMD in men could be caused by endothelial flow-dependent dysfunction because of no significant differences in popliteal artery NTG-mediated vasodilation between young and middle-aged men.

This study demonstrated that aging is related to a decrease in endothelial function in healthy men, partially manifesting as impaired popliteal FMD. However, as the underlying mechanism remains unclear, we also measured FMD together with plasma NOx and ADMA levels. NO, which is produced within the endothelium by the enzyme NO synthase (NOS) with L-arginine as a substrate, regulates many antiatherogenic effects such as vasodilation and modulation of vascular smooth muscle cells [36]. It also modulates many processes involved in aging. Sverdlov et al. [9] recently reported that aging was independently associated with impaired NO generation and its effects. It has also been demonstrated that plasma ADMA levels have a good correlation with age and reflect a vascular degenerative process associated with aging [37]. Our study showed that plasma NOx or ADMA levels were not significantly different by age or gender (see Table 1). However, when comparing young and middle-aged subjects, the NOx/ADMA ratio was significantly smaller in middle-aged men or tended to be smaller in middle-aged women. As previously reported [38], the ratio may be more sensitive to endothelial dysfunction. Although the relationship between plasma NO or ADMA levels and aging has been studied, little information is available regarding the correlation between FMD responses and plasma levels. Casey et al. [39] reported that systemic plasma NOx levels reflected brachial artery FMD responses, and Bauer et al. [40] reported that older subjects had impaired responses for brachial artery FMD and lower levels of plasma NOx compared with younger subjects. It has also been demonstrated that plasma ADMA levels have an inverse association with brachial artery FMD in healthy subjects [21, 41, 42]. Contrary to these reports, Gates et al. [43] reported that the expression of endothelial cell ADMA protein was not higher in older adults than in younger adults, and they suggested that competitive inhibition of L-arginine binding sites on endothelial NOS by ADMA was not an important mechanism contributing to age-related loss of brachial artery FMD responses in healthy subjects. Consistent with their report, we also observed that brachial artery FMD was not correlated with plasma NOx or ADMA levels in healthy men and women. Of particular interest was the observation that good correlations were found between these plasma levels and popliteal artery FMD in men. This finding suggests that impaired endothelial function in the leg conduit artery with aging may be at least partially explained by NO bioavailability or ADMA levels in men, but not in women. In women, endothelial flow-dependent function may be modulated by other additional factors without plasma NOx and ADMA. Mendelsohn [44] reported that estrogens preserved endothelial-dependent vasodilatory function by increasing NO release and by protecting NO from inactivation by ROS. Estrogens have also been reported to inhibit the synthesis of endothelin-1, which is a vasoconstrictor that opposes the effects on NO [45]. Moreau et al. [46] reported that plasma endothelin-1 concentrations were lower in premenopausal compared with postmenopausal women. Thus, the favorable effect of sex hormones may be associated in part with preserved FMD responses in women, and this may be the reason why both brachial and popliteal artery FMD of women did not correlate with plasma NOx and ADMA.

There were several limitations to the present study. First, a relatively small number of subjects were evaluated. Second, we used first-generation equipment to measure the
FMD responses, and we could not assess shear stress after deflation of the cuff. Since shear stress is closely related to FMD responses, the normalization of FMD with shear stress may contribute to better understanding of the differences in brachial and popliteal endothelial function with aging. Finally, we examined the association between brachial and popliteal artery FMD responses and plasma ADMA levels that were measured as systemic circulating protein. However, systemic plasma ADMA levels may not reflect local ADMA levels in the tissues, where ADMA may have more potent and direct regulatory roles. We cannot estimate how ADMA expressed in leg or arm arteries is associated with each endothelial-dependent dilation function.

Conclusion

We demonstrated that popliteal artery FMD was significantly lower than brachial artery FMD in healthy middle-aged men, but not in young men or women. We also observed that popliteal artery FMD showed a negative correlation with plasma ADMA levels and a positive correlation with plasma NOx levels as well as with the ratio of plasma NOx and ADMA levels in healthy men, but not in women. These findings suggest that competitive inhibition of L-arginine by ADMA may lead to impaired popliteal artery endothelium-dependent dilation in healthy men until the early 50s.

Acknowledgements

We thank the clinical laboratory technologists at Iwate Prefectural Central Hospital.

Funding

This study received no specific grants from any funding agency in the public, commercial, or not-for-profit sectors.

Compliance with ethical standards

Conflict of interest

The authors declare no conflicts of interest.

Ethical statements

Protocol approval and written informed consent were obtained according to the standards of the ethics committee of the Iwate Prefectural Central Hospital, in accordance with the principles outlined in the Declaration of Helsinki.

Open Access

This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. VanderLaan PA, Reardon CA, Getz GS. Site specificity of atherosclerosis: site-selective responses to atherosclerotic modulators. Arterioscler Thromb Vase Biol. 2004;24:12–22.
2. Newman AB, Siscovich DS, Manolio TA, et al. Ankle-arm index as a marker of atherosclerosis in the cardiovascular health study. Circulation. 1993;88:837–45.
3. Frangos SG, Gahtan V, Sumpio B. Localization of atherosclerosis: role of hemodynamics. Arch Surg. 1999;134:1142–9.
4. Kuviv JT, Karas RH. Clinical utility of endothelial function testing: ready for prime time? Circulation. 2003;107:3243–7.
5. Yeboah J, Crouse JR, Hsu FC, et al. Brachial flow-mediated dilation predicts incident cardiovascular events in older adults: the cardiovascular health study. Circulation. 2007;115:2390–7.
6. Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 1992;340:1111–5.
7. Anderson TJ, Uehata A, Gerhard MD, et al. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol. 1995;26:1235–41.
8. Leung WH, Lau CP, Wong CK. Beneficial effect of cholesterol lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients. Lancet. 1993;341:1496–500.
9. Sverdlov AL, Ngo DT, Chan WP, et al. Aging of the nitric oxide system: are we as old as our NO? J Am Heart Assoc. 2014;3:e000973. https://doi.org/10.1161/JAHA.114.000973.
10. Taddei S, Virdis A, Mattei P, et al. Aging and endothelial function in normotensive subjects and patients with essential hypertension. Circulation. 1995;91:1981–7.
11. Celermajer DS, Sorensen KE, Spiegelhalter DJ, et al. Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women. J Am Coll Cardiol. 1994;24:471–6.
12. Hashimoto M, Akishita M, Eto M, et al. Modulation of endothelium-dependent flow-mediated dilatation of the brachial artery by sex and menstrual cycle. Circulation. 1995;92:3431–5.
13. Levenson J, Pessana F, Gariepy J, et al. Gender differences in wall shear-mediated brachial artery vasoconstriction and vasodilation. J Am Coll Cardiol. 2001;38:1668–744.
14. Trinity JD, Groot HJ, Layec G, et al. Passive leg movement and nitric oxide-mediated vascular function: the impact of age. Am J Physiol Heart Circ Physiol. 2015;308:H672–H679679.
15. DeSouza CA, Clevenger CM, Greiner JJ, et al. Evidence for agonist-specific endothelial vasodilator dysfunction with ageing in healthy humans. J Physiol. 2002;542:255–62.
16. Cooke JP. Asymmetrical dimethylarginine: the Uber marker? Circulation. 2004;109:1813–8.
17. Palmer RM, Ferrigie AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 1987;327:524–6.
18. Widlansky ME, Gokce N, Keaney JF Jr, et al. The clinical implications of endothelial dysfunction. J Am Coll Cardiol. 2003;42:1149–60.
19. Böger RH, Bode-Böger SM, Szuba A, et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation. 1998;98:1842–7.
20. Yasuda S, Miyazaki S, Kanda M, et al. Intensive treatment of risk factors in patients with type-2 diabetes mellitus is associated with improvement of endothelial function coupled with a reduction in the levels of plasma asymmetric dimethylarginine and endogenous inhibitor of nitric oxide synthase. Eur Heart J. 2006;27:1159–65.
21. Juonala M, Viikari JS, Aliftan G, et al. Brachial artery flow-mediated dilation and asymmetrical dimethylarginine in...
the cardiovascular risk in young Finns study. Circulation. 2007;116:1367–73.
22. Ardigo D, Stiehlinger M, Franzini L, et al. ADMA is independently related to flow-mediated vasodilation in subjects at low cardiovascular risk. Eur J Clin Investig. 2007;37:263–9.
23. Corretti MC, Anderson TJ, Benjamin EJ, International Brachial Artery Reactivity Task Force, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002;39:257–65.
24. Parker BA, Ridout SJ, Proctor DN. Age and flow-mediated dilation: a comparison of dilatory responsiveness in the brachial and popliteal arteries. Am J Physiol Heart Circ Physiol. 2006;291:H3043–H3049.
25. Shimada T, Murakami Y, Hashimoto M, et al. Impairment of serotonin-mediated nitric oxide release across the coronary bed in patients with coronary spastic angina. Am J Cardiol. 1999;83:953–5.
26. Matsuoka H, Itoh S, Kimoto M, et al. Asymmetrical dimethylarginine, an endogenous nitric oxide inhibitor, in experimental hypertension. Hypertension. 1997;29:242–7.
27. Wang JC, Bennett M. Aging and atherosclerosis: mechanism, functional consequences, and potential therapeutics for cellular senescence. Circ Res. 2012;111:245–59.
28. Corretti MC, Plotnick GD, Vogel RA. The effects of age and gender on brachial artery endothelium-dependent vasoactivity are stimulus-dependent. Clin Cardiol. 1995;18:471–6.
29. Jensen-Urstad K, Johansson J. Gender difference in age-related changes in vascular function. J Intern Med. 2001;250:29–36.
30. Hussein AA, Uno K, Wolski K, et al. Peripheral arterial disease and progression of coronary atherosclerosis. J Am Coll Cardiol. 2011;57:1220–5.
31. Sanada H, Higashi Y, Goto C, et al. Vascular function in patients with lower extremity peripheral arterial disease: a comparison of functions in upper and lower extremities. Atherosclerosis. 2005;178:179–85.
32. Nishiyama SK, Wray DW, Richardson RS. Aging affects vascular structure and function in a limb-specific manner. J Appl Physiol. 2008;105:1661–700.
33. Harris RA, Tedjasaputra V, Zhao J, et al. Premenopausal women exhibit an inherent protection of endothelial function following a high-fat meal. Reprod Sci. 2012;19:221–8.
34. Moreau KL, Gavin KM, Plum AE, et al. Ascorbic acid selectively improves large elastic artery compliance in postmenopausal women. Hypertension. 2005;45:1107–12.
35. Charakida M, Masi S, Lüscher TF, et al. Assessment of atherosclerosis: the role of flow-mediated dilatation. Eur Heart J. 2010;31:2854–61.
36. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115–26.
37. Miyazaki H, Matsuoka H, Cooke JP, et al. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation. 1999;99:1141–6.
38. Xu L, Wang B, Kaur K, et al. NOx and ADMA changes with focal ischemia, amelioration with the chaperonin GroEL. Neurosci Lett. 2007;418:201–4.
39. Casey DP, Beck DT, Braith RW. Systemic plasma levels of nitrite/nitrate (NOx) reflect brachial flow-mediated dilation responses in young men and women. Clin Exp Pharmacol Physiol. 2007;34:1291–3.
40. Lauer T, Heiss C, Balzer J, et al. Age-dependent endothelial dysfunction is associated with failure to increase plasma nitrite in response to exercise. Basic Res Cardiol. 2008;103:291–7.
41. Antoniades C, Domenchenous M, Tousoulis D, et al. Role of asymmetrical dimethylarginine in inflammation-induced endothelial dysfunction in human atherosclerosis. Hypertension. 2011;58:93–8.
42. Melikian N, Wheatcroft SB, Ogah OS, et al. Asymmetric dimethylarginine and reduced nitric oxide bioavailability in young black African men. Hypertension. 2007;49:873–7.
43. Gates PE, Boucher ML, Silver AE, et al. Impaired flow-mediated dilation with age is not explained by L-arginine bioavailability or endothelial asymmetric dimethylarginine protein expression. J Appl Physiol. 2007;102:63–71.
44. Mendelsohn ME. Mechanisms of estrogen action in the cardiovascular system. J Steroid Biochem Mol Biol. 2000;74:337–43.
45. Yanagisawa M. The endothelin system. A new target for therapeutic intervention. Circulation. 1994;89:1320–2.
46. Moreau KL, Meditz A, Deane KD, et al. Tetrahydrobiopterin improves endothelial function and decreases arterial stiffness in estrogen-deficient postmenopausal women. Am J Physiol Heart Circ Physiol. 2012;302:H1211–H1218.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.